

**Appendix Table.** Clinical findings in rhesus monkeys infected with Marburg virus and given postexposure treatment with a recombinant VSV vector expressing the Marburg virus GP 24 h after challenge (animals 1–6) or 48 h after challenge (animals 7–12)\*†

Animal no.‡	Day 6	Day 10	Day 14	Outcome
1				Survived
2		ALT↑↑↑, AST↑↑		Survived
3		Mild rash, anorexia, thrombocytopenia, lymphopenia, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑, BUN↑↑, UA↑		Died, day 12
4		Thrombocytopenia, ALT↑↑↑, AST↑↑↑	AST↑↑	Survived
5		AST↑		Survived
6				Survived
Control 1		Fever, severe rash, anorexia, depression, lymphopenia, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑, UA↑		Died, day 12
7		Thrombocytopenia, anorexia, ALT↑↑↑, AST↑↑	ALT↑↑↑	Survived
8	Fever	Mild rash, anorexia, thrombocytopenia, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑, UA↑		Died, day 12
9		Moderate rash, anorexia, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑		Died, day 11
10		ALT↑↑↑, AST↑↑		Survived
11		Moderate rash, anorexia, depression, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑, CRE↑, UA↑		Died, day 11
12		Severe rash, anorexia, depression, thrombocytopenia, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑, CRE↑, UA↑		Died, day 10
Control 2	Lymphopenia	Moderate rash, anorexia, depression, ALP↑, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑↑		Died, day 12
Control 3		Severe rash, anorexia, depression, thrombocytopenia, ALT↑↑↑, AST↑↑↑, GGT↑, TBIL↑↑, UA↑		Died, day 11

\*GP, glycoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; TBIL, total bilirubin; BUN, blood urea nitrogen; CRE, creatinine; UA, uric acid; ↑, 2–3-fold increase; ↑↑, 4–5-fold increase; ↑↑↑, >5-fold increase.

†Fever was defined as a temperature >2.5°F over baseline or at least 1.5°F over baseline and ≥103.5°F. Mild rash consisted of focal areas of petechiae covering <10% of the skin; moderate rash, areas of petechiae covering 10%–40% of the skin; severe rash, areas of petechiae and/or echymosis covering >40% of the skin. Lymphopenia and thrombocytopenia were defined by a ≥35% drop in numbers of lymphocytes or platelets, respectively.

‡Control animals received a recombinant vesicular stomatitis virus vector expressing a nonspecific glycoprotein at 24 h (control 1) or 48 h (control 2) or were given no treatment (control 3).